Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma

Journal of Neuro-Oncology

Volumn 92, Issue 1, 2009, Pages 57-63

  Mikkelsen, T ^a,b,c   Doyle, T ^a,b   Anderson, J ^a,b   Margolis, J ^d   Paleologos, N ^e   Gutierrez, J ^a,c   Croteau, D ^a   Hasselbach, L ^a,c   Avedissian, R ^a   Schultz, L ^b,c  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c Ford Hospital   (United States)

^d WILLIAM BEAUMONT HOSPITAL   (United States)

^e EVANSTON HOSPITAL   (United States)

Author keywords

Anaplastic oligodendroglioma; Single agent chemotherapy; Temozolomide

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; ERLOTINIB; HYDROXYUREA; IMATINIB; IRINOTECAN; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; THALIDOMIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME LOSS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; LEUKOCYTE; LIVER DISEASE; LYMPHOCYTOPENIA; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPHIL; OLIGODENDROGLIOMA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RECURRENT CANCER; REPEATED DRUG DOSE; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; HUMANS; KAPLAN-MEIERS ESTIMATE; LOSS OF HETEROZYGOSITY; OLIGODENDROGLIOMA; PROGNOSIS; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 59349092347     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9735-x     Document Type: Article

References (15)

1. Cairncross JG, Ueki K, Zlatescu MC et al (1998) Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479. doi: 10.1093/jnci/90.19.1473
2. Ino Y, Betensky RA, Zlatescu MC et al (2001) Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin Cancer Res 7:839-845
3. Jenkins RB, Blair H, Ballman KV et al (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852-9861. doi: 10.1158/ 0008-5472.CAN-06-1796
4. Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707-2714. doi: 10.1200/ JCO.2005.04.3414
5. van den Bent MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European organisation for research and treatment of cancer phase III trial. J Clin Oncol 24:2715-2722. doi: 10.1200/JCO.2005.04.6078
6. Mohile N, Forsyth P, Stewart D et al (2008) A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: An interim analysis. J Neurooncol 89:187-193. doi: 10.1007/s11060-008-9603-8
7. Kouwenhoven MC, Kros JM, French PJ et al (2006) 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer 42:2499-2503. doi: 10.1016/ j.ejca.2006.05.021
8. Taliansky-Aronov A, Bokstein F, Lavon I, Siegal T (2006) Temozolomide treatment for newly diagnosed anaplastic oligodendrogliomas: A clinical efficacy trial. J Neurooncol 79:153-157. doi: 10.1007/s11060-005-9020-1
9. Abrey LE, Louis DN, Paleologos N et al (2007) Oligodendroglioma study G: survey of treatment recommendations for anaplastic oligodendroglioma. Neuro Oncol 9:314-318. doi: 10.1215/15228517-2007-002
10. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
11. Bogler O, Newsham I (2002) Studying the heterogeneity of brain tumors using medium throughput LOH analysis. Cytometry 47:52-55. doi: 10.1002/ cyto.10035
12. Cairncross J, Macdonald D, Ramsay D (1992) Aggressive oligodendroglioma: A chemosensitive tumor. Neurosurgery 3:78-82
13. Bryant J, Day R (1995) Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 51:1372-1383. doi: 10.2307/2533268
14. Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ (2007) A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest 87:392-397
15. Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354. doi: 10.1056/ NEJM200011093431901